Tradestie Institutional Equity Comparison Engine
PHIO vs CNSY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PHIO Overall Edge
PHIO Captures Institutional Edge (3โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Phio Pharmaceuticals Corp. Common Stock (PHIO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, PHIO trades at 0.3x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CNSY at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, PHIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CNSY sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
PHIO
PHIO 0.3x vs CNSY N/M Fwd P/E
Growth & Margin Winner
PHIO
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner
PHIO
1Y -48.2% vs -79.5% ยท 52W Pos 2% vs 8%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
PHIO
NASDAQ
Phio Pharmaceuticals Corp. Common Stock
Pharmaceutical Preparations
$0.74
-4.02% 1D
Market Cap
$9.7M
1M Return
-15.05%
1Y Return
-48.25%
Forward P/E
0.3x
Unified AI Score
42.8 / 100
HOLD
Tech 26.0
Fund 48.0
Flow 50.0
Mom 64.0
CNSY
US Equity
CNSY
Institutional Equity
$0.72
-24.24% 1D
Market Cap
N/A
1M Return
-57.65%
1Y Return
-79.55%
Forward P/E
N/M
Unified AI Score
47.6 / 100
HOLD
Tech 65.0
Fund 55.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PHIO -48.25%
CNSY -79.55%
Spread: +51.39 pp (PHIO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
PHIO TTM Op. Margin: 0.0%
CNSY TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PHIO vs CNSY. Trailing 12-month operating profitability (PHIO 0.0% vs CNSY N/A) and valuation multiples (PHIO 0.3x vs CNSY N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PHIO | CNSY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $9.7M | N/A | Larger Scale | PHIO |
| Trailing P/E Ratio Valuation | 0.3x | N/M | Lower Multiple | PHIO |
| Forward P/E Ratio Valuation | 0.3x | N/M | Lower Multiple | PHIO |
| Revenue Growth (YoY) Growth | +0.0% | N/A | Higher Growth | PHIO |
| Operating Margin (TTM) Profitability | 0.0% | N/A | Higher Margin | PHIO |
| Net Profit Margin Profitability | 0.0% | N/A | Higher Margin | PHIO |
| Return on Equity (ROE) Capital Efficiency | -113.7% | N/A | Higher ROE | PHIO |
| 52-Week Range Position Momentum | 2% ($1โ$2) | 8% ($0โ$4) | Stronger Trend | CNSY |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 54% Vol | 2.54ฮฒ ยท 228% Vol | Lower Realized Risk | PHIO |
| Unified Institutional Score Composite Signal | 42.8 / 100 (HOLD) | 47.6 / 100 (HOLD) | Higher Composite | CNSY |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PHIO vs CNSY Buy Guide
PHIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CNSY
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PHIO nor CNSY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.